| 2016-12-01 07:13:24|
CYCC 07:13 12/01 12/01/16
Cyclacel says data shows CYC140 therapeutic potential
Cyclacel Pharmaceuticals announced the presentation of preclinical data demonstrating the therapeutic potential of the Company's novel polo-like kinase, or PLK, 1 inhibitor, CYC140, as a targeted anti-cancer agent. The data demonstrates that CYC140 is a selective PLK1 inhibitor which preferentially induces growth inhibition and cell death in malignant versus non-malignant cells. The data were presented at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany.